NDA 211039, held by Bausch Lomb Ireland. Benoxinate Hydrochloride; Fluorescein Sodium.
As of Nov 15, 2026, NDA 211039 (Fluorescein Sodium And Benoxinate Hydrochloride), held by Bausch Lomb Ireland, was first approved by FDA on Mar 9, 2020, with 0 approved supplements and 1 published complete response letter.
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a combination of fluorescein sodium, a disclosing agent and benoxinate hydrochloride, a local ester anesthetic indicated for procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 9, 2020 | Original applicationNew combination · Standard review | Approved |
| Letter | Product | Now |
|---|---|---|
| Jul 19, 2019 | Fluorescein sodium and benoxinate hydrochloride | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluorescein Sodium And Benoxinate Hydrochloride0.4%;0.3% · solution/drops;ophthalmic | Benoxinate Hydrochloride; Fluorescein Sodium | RxReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters